FY2025 EPS Estimates for Exelixis Boosted by Zacks Research

Exelixis, Inc. (NASDAQ:EXEL) – Analysts at Zacks Research boosted their FY2025 earnings per share (EPS) estimates for Exelixis in a research note issued on Tuesday, February 3rd. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings of $2.65 per share for the year, up from their prior forecast of $2.55. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ Q4 2025 earnings at $0.75 EPS, Q1 2026 earnings at $0.61 EPS, Q2 2026 earnings at $0.63 EPS, Q3 2026 earnings at $0.68 EPS, Q4 2026 earnings at $0.83 EPS, FY2026 earnings at $2.76 EPS, Q1 2027 earnings at $0.76 EPS, Q2 2027 earnings at $0.91 EPS, Q3 2027 earnings at $0.92 EPS, Q4 2027 earnings at $1.07 EPS and FY2027 earnings at $3.65 EPS.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. The firm had revenue of $597.76 million for the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The company’s revenue was up 10.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.47 earnings per share.

Other analysts have also recently issued research reports about the stock. Barclays upped their price objective on shares of Exelixis from $41.00 to $44.00 and gave the company an “equal weight” rating in a research report on Wednesday. Wolfe Research assumed coverage on Exelixis in a report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Exelixis in a research report on Thursday, January 22nd. Leerink Partners upgraded Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a research report on Tuesday, October 21st. Finally, Oppenheimer restated a “market perform” rating and set a $36.00 target price on shares of Exelixis in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $46.16.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $43.90 on Thursday. The company has a 50 day moving average price of $43.69 and a two-hundred day moving average price of $41.00. The company has a market capitalization of $11.77 billion, a PE ratio of 18.52, a PEG ratio of 0.72 and a beta of 0.42. Exelixis has a 52 week low of $32.38 and a 52 week high of $49.62.

Hedge Funds Weigh In On Exelixis

Hedge funds and other institutional investors have recently made changes to their positions in the stock. TriaGen Wealth Management LLC acquired a new position in shares of Exelixis in the 3rd quarter valued at about $2,024,000. Allianz Asset Management GmbH increased its holdings in Exelixis by 153.3% in the third quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company’s stock worth $101,720,000 after purchasing an additional 1,490,520 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in Exelixis in the second quarter valued at approximately $321,000. Winnow Wealth LLC acquired a new position in Exelixis in the third quarter valued at approximately $1,017,000. Finally, Capital Fund Management S.A. boosted its holdings in shares of Exelixis by 6.6% during the 2nd quarter. Capital Fund Management S.A. now owns 283,639 shares of the biotechnology company’s stock worth $12,501,000 after buying an additional 17,673 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Dana Aftab sold 48,383 shares of Exelixis stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $42.50, for a total transaction of $2,056,277.50. Following the transaction, the executive vice president directly owned 664,778 shares of the company’s stock, valued at approximately $28,253,065. The trade was a 6.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Patrick J. Haley sold 34,187 shares of the company’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $41.88, for a total value of $1,431,751.56. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 245,235 shares of company stock worth $10,490,600 in the last three months. 2.82% of the stock is currently owned by company insiders.

Key Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research upgraded Exelixis from a “hold” to a “strong‑buy,” signaling increased analyst conviction that the company’s growth story is improving. Read More.
• Positive Sentiment: Zacks issued broad upward revisions to Exelixis’ earnings outlook — raising FY2026 to $2.76 from $2.34 and FY2027 to $3.65 (previously $3.30), and lifting several quarterly estimates (e.g., Q1‑Q4 2026 and Q1‑Q4 2027). These higher forward EPS forecasts support a re‑rating and provide a clearer path to earnings growth. Read More.
• Positive Sentiment: Zacks published a bullish write‑up, “3 Reasons Why Growth Investors Shouldn’t Overlook Exelixis,” highlighting growth attributes that could help EXEL outperform — a narrative that can attract growth‑oriented buyers. Read More.
• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating on EXEL, providing additional sell‑side support that may encourage institutional interest. Read More.
• Neutral Sentiment: Note that Zacks’ upgraded forecasts exceed the current broader consensus (the entries cite a consensus near $2.04 for the current year). The market may await confirmation from Exelixis’ upcoming results/sales trends before other analysts materially follow, which could create short‑term volatility. Read More.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.